Avadel pharmaceuticals to present new data on lumryz™ (sodium oxybate) for extended-release oral suspension at sleep 2025

– 14 abstracts accepted, including four oral presentations – – interim analysis of real-world refresh study demonstrated clinically significant efficacy and improvement of eds for patients who switched from twice-nightly oxybate to once-at-bedtime lumryz – – data reflecting the therapeutic results of lumryz treatment in people with narcolepsy across clinical as well as real-world settings will be presented – dublin, ireland, may 29, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of lumryz as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 posters at sleep 2025, the 39th annual meeting of the associated professional sleep societies (apss), taking place june 8-11, 2025 in seattle. “post-hoc analysis of the pivotal phase 3 rest-on clinical trial, restricted to those study participants with the most severe sleepiness at baseline as measured both objectively and subjectively, showed lumryz participants with a median epworth sleepiness scale (ess) score at week 13 that was improved to the range at or below that considered normal.
AVDL Ratings Summary
AVDL Quant Ranking